SpiraCheck Ltd Analysis: $1M Raised
What is SpiraCheck Ltd?
SpiraCheck develops a breath-based test to detect gastrointestinal and other cancers by identifying volatile organic compounds. The algorithm is backed by six completed clinical biomarker trials involving 2,352 patients and ten ongoing trials with over 30,000 patients. The test aims to improve five-year relative survival for GI cancers through early detection and reduce invasive diagnostics.
Location
London, United Kingdom
Employees
1-10
Founded
2016
Funding Status
Seed
Product Features & Capabilities
- Breath-based multi-cancer early detection test identifying VOCs
- Algorithm developed by Professor George Hanna's team at Imperial College London
- Clinical validation across 16 cancer types including oesophageal, gastric, pancreatic, and colorectal
- Patented biomarker discovery methods
- Non-invasive screening for patients at high risk of GI cancers
Use Cases
Screen high-risk patients for gastrointestinal cancers using a single breath test; Rule out GI cancers in patients with symptoms; Reduce invasive diagnostic procedures through better prioritisation; Monitor treatment effectiveness by tracking disease progression; Enable early detection in under-50s with rising bowel cancer rates; Support UK's less survivable cancers taskforce goals for improved survival rates
Other Considerations
Six completed clinical biomarker trials (n=2,352; 580 with cancer); Ten ongoing grant-funded clinical trials (>30,000 patients); Developed by Professor George Hanna's team at Imperial College London; Backed by patents licensed to SpiraCheck; Recognized in UK 'Less Survivable Cancers Taskforce' reports; Attended Emerging Medtech Summit 2024
See something that needs updating? Suggest edits to this profile.